Tesamorelin

Tesamorelin is an FDA-approved growth hormone releasing hormone (GHRH) analogue, marketed as Egrifta, approved for exactly one indication: reducing excess abdominal visceral fat in HIV-infected adults with lipodystrophy. The label explicitly states it is not indicated for weight loss management, and Europe’s medicines regulator withdrew the drug’s marketing application in 2012 after finding the measured fat reduction didn’t translate into demonstrated clinical benefit. It requires IGF-1 and glucose monitoring while in use.

Ask about Tesamorelin

Research snapshot

CategoryCurrent information
Peptide categoryGHRH analogue (44-amino-acid, hexenoylated)
Primary research interestReduction of HIV-associated visceral fat (approved); body composition/anti-aging (not approved, not studied for these)
Highest available evidenceTier 1 – approved via two phase 3 RCTs, 806 patients pooled
Human research availableYes – extensive for the approved indication; none for any other use
Development statusApproved (US only)
Regulatory statusFDA-approved for one indication; EMA application withdrawn (2012); named in a 2026 FDA warning letter for unapproved-use marketing

Technical identity

Technical propertyInformation
Primary nameTesamorelin
Alternative namesEgrifta, Egrifta SV, Egrifta WR, TH9507, tesamorelin acetate
Peptide sequencetrans-3-hexenoyl-hGHRH(1-44)-NH2
Amino-acid length44 residues (full native GHRH sequence, with a hexenoyl group on the N-terminal tyrosine)
Molecular formulaC221H366N72O67S
Molecular weight5135.86 g/mol
CAS Registry Number218949-48-5
PubChem CID16137828
Chemical modificationsN-terminal hexenoylation, slows degradation
Peptide classGHRH analogue
Primary biological targetPituitary GHRH receptor
Developer or originatorTheratechnologies
Development statusApproved (US); withdrawn from EU consideration

What it is

Tesamorelin is a synthetic analogue of human growth hormone releasing hormone, the full 44 amino acid sequence with a hexenoyl group attached to the first residue. That modification is there to slow degradation. It is a prescription biologic, marketed as Egrifta, and it is the only compound on this site so far with an approved label.

FDA approved it on 10 November 2010. The application has since been converted from a new drug application to a biologics licence, and the formulation has changed twice, from the original Egrifta to Egrifta SV in 2019 and Egrifta WR in 2025.

What was approved, and for whom

The indication, verbatim from the current label: a growth hormone releasing factor analogue indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

That is the whole of it. The label carries three limitations of use, also verbatim. Long-term cardiovascular safety has not been established. Not indicated for weight loss management. There are no data to support improved compliance with antiretroviral therapies. The original 2010 label was blunter on the second point, reading not indicated for weight loss management, with a parenthetical noting a weight neutral effect.

So the label does not claim weight loss, does not claim general body-composition improvement, does not claim anything about ageing, and does not claim cardiovascular benefit. There is no approved indication in any population without HIV. The population wording has narrowed over time rather than broadened: the word adult was added after 2013.

The approved dose is 1.28 mg subcutaneously once daily on the current formulation, having been 1.4 mg on the previous one and 2 mg on the original.

There is no boxed warning. The contraindications are disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity, and pregnancy. The warnings section is headed, in order, by increased risk of neoplasms, elevated IGF-1 levels, fluid retention, glucose intolerance or diabetes, hypersensitivity, injection site reactions, and increased mortality in patients with acute critical illness.

The evidence behind the approval

Two phase 3 trials, 806 patients pooled, both randomised double-blind placebo-controlled in a 2 to 1 ratio, 26 weeks with a 26 week extension, tesamorelin 2 mg subcutaneously daily. The primary endpoint was percent change in visceral adipose tissue measured by CT at the fourth and fifth lumbar vertebrae.

Study one gave a treatment difference of minus 31 square centimetres with a 95 percent confidence interval of minus 39 to minus 24, a 20 percent difference against placebo. Study two gave minus 21 square centimetres, confidence interval minus 29 to minus 12, a 12 percent difference. Waist circumference fell by about 2 centimetres more than placebo in the first and 1 centimetre in the second. Triglycerides fell 50 milligrams per decilitre against a rise of 9 on placebo. IGF-1 rose 81 percent against a 5 percent fall.

Two features of that result matter for how the compound is used off-label. Subcutaneous fat did not change, with a pooled treatment effect of minus 0.6 percent at p equals 0.08, so the drug moved visceral fat specifically and not fat generally. And the 52 week extension showed the visceral effect sustained at minus 18 percent while treatment continued.

The dose was set by a phase 2 trial in 61 patients comparing 1 mg against 2 mg against placebo. At 2 mg, trunk fat fell 9.2 percent and reached significance. At 1 mg it fell 4.6 percent and did not. Visceral fat did not reach significance against placebo in either arm of that smaller study. That is why the pivotal programme used 2 mg, and it matters for the section below.

What dosage information circulates?

Figures in this table summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
Phase 2 dose-rangingSubcutaneous1 mg or 2 mgOnce daily12 weeksPublished human clinical trial
Approved use (Egrifta, original)Subcutaneous2 mgOnce dailyOngoing/chronicFDA label
Approved use (Egrifta SV)Subcutaneous1.4 mgOnce dailyOngoing/chronicFDA label
Approved use (Egrifta WR)Subcutaneous1.28 mgOnce dailyOngoing/chronicFDA label
Body composition, off-label (as sold)Subcutaneous1 mgOnce daily, eveningNot specifiedCommunity / vendor reported

The circulating 1 mg/day dose is specifically the dose that failed to separate from placebo in the phase 2 trial that set the approved program at 2 mg – a checkable conflict, not a vague one.

Potential benefits and research applications

Reduction of HIV-associated visceral fat (the approved use)

What is being investigated or established: reduction of visceral adipose tissue in HIV-associated lipodystrophy. Evidence: two phase 3 RCTs, 806 patients, FDA-approved on this basis. Strength: established for this specific population and endpoint. Limitation: the effect is specific to visceral fat, not general weight or fat loss; the 52-week extension showed the effect sustained only while treatment continued (it’s not a one-time fix); and Europe’s regulator found the CT-measured fat reduction didn’t demonstrate a clinical health benefit.

Weight loss and general body composition (not approved)

What is being investigated: nothing officially, the label explicitly disclaims this use (“not indicated for weight loss management”). Evidence: none for this application specifically. Strength: not established. This is the single largest gap between how tesamorelin is marketed informally and what its approval actually covers.

Anti-aging, cognitive, or metabolic effects (circulating claims)

What is being investigated: some exploratory work exists outside the approved indication, for example a cognition trial using a 1 mg dose, but nothing rises to an approved or clinically established benefit. Strength: not established.

Safety, from the label and the trials

Over the first 26 weeks, injection site reactions occurred in 25 percent of treated patients against 14 percent on placebo. Arthralgia 13 against 11 percent, myalgia 6 against 2, peripheral oedema 6 against 2. Serious treatment-emergent events in under 4 percent.

The IGF-1 numbers are the reason the label requires monitoring. Among patients treated for 26 weeks, 47 percent had IGF-1 more than two standard deviation scores above normal and 36 percent more than three, with the effect appearing as early as thirteen weeks. The label instructs prescribers to monitor IGF-1 and to consider discontinuing in patients with persistent elevations above three standard deviation scores, particularly where the response is not robust. It states directly that the effects of prolonged elevations in IGF-1 are unknown.

On glucose, elevated HbA1c at or above 6.5 percent occurred in 5 percent of treated patients against 1 percent on placebo, and the label reports an intent-to-treat hazard odds ratio for developing diabetes of 3.3 with a confidence interval of 1.4 to 9.6.

The European decision, which is the sharpest external check

An application for European marketing authorisation was withdrawn on 21 June 2012, after the committee had raised questions and received answers but with unresolved issues remaining. Per the agency withdrawal document, the committee provisional view was that the benefits of the product did not outweigh its risks.

The stated grounds are worth reading in full because they go to the heart of how tesamorelin is marketed elsewhere. Difficulty distinguishing lipodystrophy-related fat from ordinary obesity clinically. Insufficient evidence supporting the proposed patient restrictions. No demonstrated clinical health benefit despite the measured reduction in abdominal fat. Concern about raised IGF-1 as a safety issue. And absence of long-term safety data for a treatment expected to be taken long term.

Tesamorelin has no European marketing authorisation. The third of those grounds, a measured fat reduction that did not translate into demonstrated clinical benefit, is the single most useful sentence in this entry.

Regulatory status

Approved in the United States for the one indication above, under a biologics licence. Withdrawn from European consideration in the face of a negative provisional benefit-risk view. Prohibited in sport at all times, named directly in WADA section S2.2.4 among GHRH analogues alongside CJC-1293, CJC-1295 and sermorelin. And named in FDA warning letters issued on 24 August 2026 to peptide vendors, cited as an unapproved new drug introduced into interstate commerce without an approved application.

All four of those are true at once, and any account that gives only one of them is misleading.

Tesamorelin does not appear on the 503A bulk drug substances list in any category, which is not a permission. As the active ingredient of an approved drug it sits in a different statutory position from the unapproved peptides, and it is separately constrained by rules about compounding copies of commercially available drugs. No FDA document stating its 503A eligibility either way was located. Its usual blend partner, ipamorelin acetate, is in Category 2.

Frequently asked questions

Is tesamorelin FDA approved?

Yes, for one specific use: reducing visceral fat in HIV-associated lipodystrophy.

Is tesamorelin approved for weight loss?

No. The label explicitly states it is “not indicated for weight loss management.”

What is the approved dose?

1.28 mg/day (current Egrifta WR formulation), down from 2 mg originally.

Why did Europe not approve it?

The EU regulator found the measured fat reduction didn’t demonstrate a clinical health benefit, among other concerns, and the application was withdrawn in 2012.

What dosage circulates online?

Commonly 1 mg/day, which is the exact dose that failed in the trial that set the approved 2 mg dose.

What are the main risks?

Elevated IGF-1 (requiring monitoring), increased diabetes risk, injection site reactions, and label warnings for neoplasm risk and fluid retention.

Can I monitor my dose properly if I buy a tesamorelin/ipamorelin blend?

No. Blend vials are labeled by combined weight, not tesamorelin content per injection, making the label’s required IGF-1-guided dosing structurally impossible.

Is it banned in sports?

Yes, named directly in WADA S2.2.4, prohibited at all times.

How strong is the evidence?

Strong for the approved indication (two phase 3 RCTs); none exists for weight loss or other off-label uses.

Bottom line

Tesamorelin is a real, FDA-approved drug, but for exactly one thing: visceral fat reduction in HIV-associated lipodystrophy. Its label explicitly disclaims weight-loss use, and Europe’s regulator went further, withdrawing its marketing application after finding the measured effect didn’t demonstrate clinical benefit. The 1 mg/day dose that circulates informally is drawn from the real clinical record, but it’s the dose that failed in the study that determined the approved 2 mg dose. IGF-1 monitoring is a real label requirement with real teeth (elevated IGF-1 in a large share of treated patients), and that monitoring becomes impossible when tesamorelin is sold in an undisclosed-ratio blend.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Body composition, off-labelSubcutaneous1 mgOnce daily, eveningNot specified
With ipamorelin, as a blendSubcutaneousNot determinable from the vialOnce dailyNot specified

Tesamorelin circulates as lyophilised powder in vials commonly labelled 2, 5 and 10 mg under research use framing. The route is subcutaneous, the frequency is once daily, the timing is evening on a stated rationale about nocturnal growth hormone, and the dominant single-agent figure is 1 mg a day.

That figure is below every dose ever approved. It is 50 percent of the original 2 mg, about 71 percent of the 1.4 mg formulation and about 78 percent of the current 1.28 mg. For most compounds on this site the circulating figure exceeds anything studied. Here it is lower, and that is not reassuring, because 1 mg is specifically the dose that failed to separate from placebo on visceral and trunk fat in the phase 2 trial that selected 2 mg for the pivotal programme. It is a real dose from the record, attached to the wrong endpoint.

Circulating material states no cycle length, no total duration, no stopping rule and no monitoring interval. That absence is itself the finding, because the approved product requires glucose assessment before starting and IGF-1 monitoring with a discontinuation threshold.

Blends make the monitoring impossible rather than merely absent. Tesamorelin is most often mixed with ipamorelin and sold by combined total peptide weight, commonly around 9, 13 or 15 mg, at ratios in the region of 2 to 1 up to 4 to 1. Because the vial is labelled by combined weight, how much tesamorelin a single injection delivers cannot be worked out from the vial at all, so the dose cannot be compared to the approved one and cannot be adjusted against an IGF-1 result.

On citation, the answer is nothing. Across the material surveyed there is no reference to the label, no NCT number, no journal reference, and no mention of the HIV-lipodystrophy-only indication, the not-indicated-for-weight-loss limitation, the active-malignancy contraindication, the IGF-1 monitoring requirement or the diabetes hazard odds ratio of 3.3. Meanwhile the framing centres weight loss, abdominal spot reduction, muscle gain and anti-ageing, which is close to an inversion of what the label says.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Sources

  1. EGRIFTA, EGRIFTA SV and EGRIFTA WR (tesamorelin for injection) prescribing information. US Food and Drug Administration, BLA 022505, originally approved 10 November 2010. BLA 022505
  2. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. Pivotal phase 3, study one. PMID 18057338
  3. Falutz J, et al. Long-term safety and effects of tesamorelin, a GHRH analogue, in HIV patients with abdominal fat accumulation. J Acquir Immune Defic Syndr. 2010. Pivotal phase 3, study two. PMID 20101189
  4. Falutz J, et al. Effects of tesamorelin on visceral fat and metabolic parameters: pooled phase 3 analysis, n=806. J Clin Endocrinol Metab. 2010. No effect on subcutaneous fat. PMID 20554713
  5. Falutz J, et al. Phase 2 dose-ranging trial of TH9507, 1 mg versus 2 mg versus placebo, n=61. AIDS. 2005. Only the 2 mg arm reached significance on trunk fat. PMID 16052083
  6. Falutz J, et al. Effects of tesamorelin over 52 weeks: extension phase of the pivotal programme. AIDS. 2008. PMID 18690162
  7. Theratechnologies. Phase 3 trial of TH9507 in HIV-associated abdominal fat accumulation, n=412. No results posted on the registry. NCT00123253
  8. Theratechnologies. Second phase 3 trial of TH9507, n=404. No results posted on the registry. NCT00435136
  9. European Medicines Agency. Ferrer Internacional withdraws its marketing authorisation application for Egrifta (tesamorelin), 21 June 2012. CHMP provisional view that the benefits did not outweigh the risks. EMA withdrawal, 21 June 2012
  10. Ferdinandi ES, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007. PMID 17214611
  11. World Anti-Doping Agency. Prohibited List, section S2.2.4, GHRH and its analogues, naming CJC-1293, CJC-1295, sermorelin and tesamorelin. Prohibited at all times. WADA S2.2.4
  12. US Food and Drug Administration. Warning letter 734884, 24 August 2026, naming tesamorelin among products cited as unapproved new drugs under sections 301(d) and 505(a) of the FD&C Act. FDA warning letter 734884

Live registry status

These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.

TrialPhaseStatusSponsorEnrolledPrimary completionRegistry updated
TH9507 in Patients With HIV-Associated Lipodystrophy
NCT00123253
Phase 3CompletedTheratechnologies412Nov 2006Nov 27, 2013
TH9507 in Patients With HIV-Associated Lipodystrophy
NCT00435136
Phase 3CompletedTheratechnologies412Nov 2006Nov 27, 2013

Open these in the trial tracker

Research area: Growth hormone axis.

Share thisFacebookXEmail